Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer

<i>Background and Objectives:</i> Patients with human epidermal growth factor receptor 2 (HER2) -positive, hormone receptor-positive (HR-positive) metastatic breast cancer (MBC) usually undergo trastuzumab emtansine (T-DM1) therapy in subsequent lines. Combining endocrine therapy (ET) wi...

Full description

Bibliographic Details

Published in:	Medicina
Main Authors:	Oğuzcan Kınıkoğlu, Hatice Odabas, Yunus Emre Altıntaş, Anıl Yıldız, Burçin Çakan, Goncagül Akdağ, Sedat Yıldırım, Hamit Bal, Tuğba Kaya, Salih Tünbekici, Deniz Işık, Tuğba Başoğlu, Mahmut Emre Yıldırım, Nedim Turan
Format:	Article
Language:	English
Published:	MDPI AG 2024-06-01
Subjects:	metastatic breast cancer trastuzumab emtansine endocrine therapy pertuzumab plus trastuzumab
Online Access:	https://www.mdpi.com/1648-9144/60/6/951